Xenon in $646 million deal with Roche unit

10 January 2012

Canada based Xenon Pharmaceuticals, a privately-owned, clinical genetics-based drug discovery and development company, has entered into a strategic alliance with Genentech, a US subsidiary of Swiss drug major Roche (ROG: SIX), to discover and develop compounds and companion diagnostics for the potential treatment of pain.

Under the terms of the accord, Xenon will receive an undisclosed upfront payment, research funding and is eligible to receive research, development and commercialization milestone payments, totaling up to $646 million for multiple products and indications. In addition, Xenon will receive royalties on sales of products resulting from the collaboration.

Xenon and Genentech will collaborate on the discovery of new therapeutic approaches for treating pain. The agreement provides Genentech with an exclusive license to compounds and a non-exclusive license to diagnostics from Xenon for development and commercialization of products. No further details of the deal were disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK